Revealing new regulators of EGFR-P13K driven glioma proliferation and migration
揭示 EGFR-P13K 驱动神经胶质瘤增殖和迁移的新调节因子
基本信息
- 批准号:7707429
- 负责人:
- 金额:$ 8.35万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-08-01 至 2011-07-31
- 项目状态:已结题
- 来源:
- 关键词:1-Phosphatidylinositol 3-KinaseBiological AssayBiological ModelsBiologyBrain regionCandidate Disease GeneCell LineCellsCollaborationsDataDrosophila genomeDrosophila genusEnhancersEpidermal Growth Factor ReceptorFacultyGene ExpressionGene TargetingGenesGeneticGenetic ScreeningGenetic TechniquesGenetic TranscriptionGlioblastomaGliomaGrowthHumanInstitutesLaboratoriesMalignant NeoplasmsMediatingMentorsMitogensModelingMolecularMusMutateMutationNeoplasm MetastasisNeoplasmsNeurogliaOrthologous GenePathogenesisPathway interactionsPatternPharmaceutical PreparationsPhasePhenotypePlayPositioning AttributeProteinsRNA InterferenceResearchResearch PersonnelRiskRoleSignal PathwaySignal TransductionSirolimusSystemTestingTrainingTranslatingautocrinebasecombinatorialdesigngenetic analysishomeodomainhuman diseaseinsightmedical schoolsmigrationmouse modelmutantneoplasticnerve stem cellnoveloverexpressionpublic health relevanceresearch studyresponsetherapeutic targettranscription factortumor
项目摘要
Constitutive activation of the EGFR-Ras and PI-3 kinase (PI3K) signaling pathways is a common feature in human GBM and is sufficient to cause glioblastoma-like phenotypes in mouse models. How these signaling pathways specifically control glial pathogenesis is unclear. A novel Drosophila model was created to understand the molecular basis of EGFR and PI3K driven GBM. When targeted to glia and glial precursors using genetic techniques, co-activation of EGFR and RISK in Drosophila gives rise to neoplastic, invasive glial cells that create transplantable tumor-like growths, mimicking the human disease. Genetic analyses demonstrate that EGFR and PI3K induce Drosophila glial neoplasia, in part, via a combinatorial genetic network that includes genes and pathways also commonly mutated or activated in human GBM. This model has been used to identify new regulators of glial neoplasia through genetic screens and phenotypic analyses. The genes identified in these screens represent excellent candidates for genes directly involved in the pathogenesis of human GBM. Therefore, expression and function of mammalian orthologs of Drosophila modifiers will be examined in human tumors, genetically defined mouse GBMs, and GBM cell lines. During the mentored years, one already identified Drosophila modifier gene and its mammalian ortholog will be subject to detailed analysis in both Drosophila and mammalian systems. These studies will be performed in the laboratories of my mentor, Dr. John Thomas, an expert Drosophila neurobiologist, my collaborator Dr. Inder Verma, an expert mouse geneticist and cancer biologist, and my co-mentors Drs. Webster Cavenee and Frank Furnari, both experts in GBM biology. This will provide me with the training necessary to obtain an independent faculty position at a research intensive medical school, where I will expand these studies to include another 2-3 genes. PUBLIC HEALTH RELEVANCE: These studies are expected to provide key insights into glioma pathogenesis, including the identity of genes involved in tumor cell migration and invasiveness. The products of these genes may represent excellent targets for therapeutics.
EGFR-Ras和PI-3激酶(PI 3 K)信号通路的组成性激活是人GBM的常见特征,足以在小鼠模型中引起胶质母细胞瘤样表型。这些信号通路如何特异性控制神经胶质的发病机制尚不清楚。建立了一种新的果蝇模型,以了解EGFR和PI 3 K驱动的GBM的分子基础。当使用遗传技术靶向神经胶质和神经胶质前体时,果蝇中EGFR和RISK的共激活引起肿瘤性、侵袭性神经胶质细胞,其产生可移植的肿瘤样生长,模仿人类疾病。遗传分析表明,EGFR和PI 3 K诱导果蝇神经胶质瘤形成,部分是通过一个组合遗传网络,包括基因和途径也通常突变或激活人类GBM。该模型已被用于通过遗传筛选和表型分析来识别神经胶质瘤形成的新调节因子。在这些筛选中鉴定的基因代表了直接参与人GBM发病机制的基因的优秀候选者。因此,将在人类肿瘤、遗传定义的小鼠GBM和GBM细胞系中检查果蝇修饰剂的哺乳动物直系同源物的表达和功能。在指导的几年里,一个已经确定的果蝇修饰基因及其哺乳动物直系同源物将在果蝇和哺乳动物系统中进行详细的分析。这些研究将在我的导师、果蝇神经生物学家约翰·托马斯博士、我的合作者、小鼠遗传学家和癌症生物学家英德·维尔马博士以及我的共同导师韦伯斯特·卡维尼博士和弗兰克·弗纳里博士的实验室中进行,他们都是GBM生物学方面的专家。这将为我提供必要的培训,以获得在研究密集型医学院的独立教师职位,在那里我将扩大这些研究,包括另外2-3个基因。公共卫生关系:这些研究有望为胶质瘤发病机制提供关键见解,包括参与肿瘤细胞迁移和侵袭的基因的身份。这些基因的产物可能是治疗的极好靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Renee D Read其他文献
Renee D Read的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Renee D Read', 18)}}的其他基金
Human Organoid Models for Pediatric High-Grade Gliomas
儿童高级别胶质瘤的人体类器官模型
- 批准号:
10727450 - 财政年份:2023
- 资助金额:
$ 8.35万 - 项目类别:
Verteporfin as a YAP/TAZ inhibitor for treatment of glioblastoma
维替泊芬作为 YAP/TAZ 抑制剂治疗胶质母细胞瘤
- 批准号:
10737348 - 财政年份:2023
- 资助金额:
$ 8.35万 - 项目类别:
MET kinase fusions in pediatric glioblastoma
儿童胶质母细胞瘤中的 MET 激酶融合
- 批准号:
10690229 - 财政年份:2022
- 资助金额:
$ 8.35万 - 项目类别:
MET kinase fusions in pediatric glioblastoma
儿童胶质母细胞瘤中的 MET 激酶融合
- 批准号:
10373782 - 财政年份:2021
- 资助金额:
$ 8.35万 - 项目类别:
MET kinase fusions in pediatric glioblastoma
儿童胶质母细胞瘤中的 MET 激酶融合
- 批准号:
10756382 - 财政年份:2021
- 资助金额:
$ 8.35万 - 项目类别:
MET kinase fusions in pediatric glioblastoma
儿童胶质母细胞瘤中的 MET 激酶融合
- 批准号:
10532158 - 财政年份:2021
- 资助金额:
$ 8.35万 - 项目类别:
Mechanisms of RIOK2 function in glioblastoma
RIOK2在胶质母细胞瘤中的功能机制
- 批准号:
10232051 - 财政年份:2017
- 资助金额:
$ 8.35万 - 项目类别:
Revealing new regulators of EGFR-P13K driven glioma proliferation and migration
揭示 EGFR-P13K 驱动神经胶质瘤增殖和迁移的新调节因子
- 批准号:
8668168 - 财政年份:2012
- 资助金额:
$ 8.35万 - 项目类别:
Revealing new regulators of EGFR-P13K driven glioma proliferation and migration
揭示 EGFR-P13K 驱动神经胶质瘤增殖和迁移的新调节因子
- 批准号:
8504550 - 财政年份:2012
- 资助金额:
$ 8.35万 - 项目类别:
Revealing new regulators of EGFR-P13K driven glioma proliferation and migration
揭示 EGFR-P13K 驱动神经胶质瘤增殖和迁移的新调节因子
- 批准号:
8450950 - 财政年份:2012
- 资助金额:
$ 8.35万 - 项目类别:
相似海外基金
Establishment of a new biological assay using Hydra nematocyst deployment
利用水螅刺丝囊部署建立新的生物测定方法
- 批准号:
520728-2017 - 财政年份:2017
- 资助金额:
$ 8.35万 - 项目类别:
University Undergraduate Student Research Awards
POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER) AFTER RADIOLOGICAL AND NUCLEAR EVENTS.
用于确定放射和核事件后组织特异性吸收电离辐射剂量(生物剂量计)的护理点生物测定。
- 批准号:
10368760 - 财政年份:2017
- 资助金额:
$ 8.35万 - 项目类别:
POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER) AFTER RADIOLOGICAL AND NUCLEAR EVENTS.
用于确定放射和核事件后组织特异性吸收电离辐射剂量(生物剂量计)的护理点生物测定。
- 批准号:
10669539 - 财政年份:2017
- 资助金额:
$ 8.35万 - 项目类别:
POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER) AFTER RADIOLOGICAL AND NUCLEAR EVENTS.
用于确定放射和核事件后组织特异性吸收电离辐射剂量(生物剂量计)的护理点生物测定。
- 批准号:
9570142 - 财政年份:2017
- 资助金额:
$ 8.35万 - 项目类别:
POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER) AFTER RADIOLOGICAL AND NUCLEAR EVENTS.
用于确定放射和核事件后组织特异性吸收电离辐射剂量(生物剂量计)的护理点生物测定。
- 批准号:
9915803 - 财政年份:2017
- 资助金额:
$ 8.35万 - 项目类别:
COVID-19 Supplemental work: POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER).
COVID-19 补充工作:用于确定组织特异性吸收电离辐射剂量的护理点生物测定(生物剂量计)。
- 批准号:
10259999 - 财政年份:2017
- 资助金额:
$ 8.35万 - 项目类别:
Drug discovery based on a new biological assay system using Yeast knock-out strain collection
基于使用酵母敲除菌株收集的新生物测定系统的药物发现
- 批准号:
21580130 - 财政年份:2009
- 资助金额:
$ 8.35万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Machine learning for automatic gene annotation using high-throughput biological assay data
使用高通量生物测定数据进行自动基因注释的机器学习
- 批准号:
300985-2004 - 财政年份:2005
- 资助金额:
$ 8.35万 - 项目类别:
Postdoctoral Fellowships
Machine learning for automatic gene annotation using high-throughput biological assay data
使用高通量生物测定数据进行自动基因注释的机器学习
- 批准号:
300985-2004 - 财政年份:2004
- 资助金额:
$ 8.35万 - 项目类别:
Postdoctoral Fellowships














{{item.name}}会员




